Publicaties over de HOME-studie (1-12) en vanuit het METGEN consortium (13-14)
- Wulffelé MG, Kooy A, Lehert P, Bets D, Oom JA, Borger van der Burg B, Donker AJM, Stehouwer CDA. Discontinuation of metformin in type 2 diabetes patients treated with insulin. Neth J Med 2002; 60: 249-252.
- Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJM, Stehouwer CDA. Combination of insulin and metformin in the treatment of type 2 diabetes. Diabetes Care 2002; 25: 2133-2140.
- Wulffelé MG, Kooy A, Lehert P, Bets D, Oom JA, Borger van der Burg B, Donker AJM, Stehouwer CDA. Effect of short-term treatment with metformin on serum concentrations of homocysteine, folate and vitamin B12 in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Int Med 2003; 254: 455-463.
- Wulffelé MG, Kooy A, De Zeeuw D, Stehouwer CDA, Gansevoort RT. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Int Med 2004; 256: 1-14.
- Jager J de, Kooy A, Lehert Ph, Bets D, Donker AJM, Stehouwer CDA. Effects of short-term treatment with metformin on markers of endothelial function and inflammatory activity in type 2 diabetes mellitus: a randomized, placebo-controlled trial. J Int Med 2005; 257: 100-109.
- Wulffelé MG, Kooy A, Lehert Ph, Bets D, Donker AJM, Stehouwer CDA. Does metformin decrease blood pressure in patients with type 2 diabetes intensively treated with insulin? Diabetic Medicine 2005; 22: 907-913.
- Jager J de, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CDA. Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study. Arterioscler Thromb Vasc Biol. 2006; 26: 1086-1093.
- Kooy A, Jager J de, Lehert P, Bets D, Wulffelé MG, Donker AJM, Stehouwer CDA. Long term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. Archives of Internal Medicine 2009; 169: 616-625.
- Kooy A, Jager J de, Lehert P, Bets D, Wulffelé MG, Donker AJM, Stehouwer CDA. Benefits of the addition of metformin to insulin therapy in type 2 diabetes. Favourable weight development with less macrovascular complications. Ned Tijdschr Geneeskd 2009; 153: 1005-1013.
- Kooy A. Continuation of metformin after introduction of insulin in type 2 diabetes. Editorial. BMJ 2009; 339: b4227.
- Jager J de, Kooy A, Lehert P, Wulffelé MG, Kolk J van der, Bets D, Verburg J, Donker AJM, Stehouwer CDA. Long-term treatment with metformin in patients with type 2 diabetes treated with insulin and risk of vitamin B12 deficiency: a randomised, placebo-controlled trial. BMJ 2010; 340: c2181 (with Editorial: BMJ 2010; 340: c2198).
- Jager J de, Kooy A, Schalkwijk CG, Lehert P, Bets D, Wulffelé MG, Donker AJM, Stehouwer CDA. Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. J Internal Med 2014; 275: 59-70.
- Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Zidzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkác I, Kooy A, van Schaik RHN, Stehouwer CD, Logie L, MetGen Investigators, DPP investigators, ACCORD investigators, Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Wagner MJ, Innocenti F, 't Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CN, Florez JC, Giacomini KM, Pearson ER. Variation in the Glucose Transporter gene GLUT2 (SLC2A2) is associated with glycaemic response to metformin. Nature Genetics 2016; 48: 1055-59.
- Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Christensen MM, Out M, Tavendale R, Kubo M, Hedderson MM, van der Heijden AA, Klimcáková L, Pirags V, Kooy A, Brøsen K, Klovins J, Semiz S, Tkáč I, Stricker BH, Palmer CN, 't Hart LM, Giacomini KM, Pearson ER. Variants in Pharmacokinetic Transporters and Glycaemic Response to Metformin: A MetGen Meta-Analysis. Clin Pharmacol Ther. 2016 Nov 10. doi: 10.1002/cpt.567.
- Dujic T, Zhou K, Yee SW, van Leeuwen N, de Keyser CE, Javorský M, Goswami S, Zaharenko L, Hougaard Christensen MM, Out M, Tavendale R, Kubo M, Hedderson MM, van der Heijden AA, Klimcáková L, Pirags V, Kooy A, Brøsen K, Klovins J, Semiz S, Tkáč I, Stricker BH, Palmer C, 't Hart LM, Giacomini KM, Pearson ER. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis. Clin Pharmacol Ther. 2017 Jun;101(6):763-772. doi: 10.1002/cpt.567. Epub 2017 Feb 3.
- Out M, Miedema I, Jager-Wittenaar H, van der Schans C, Krijnen W, Lehert P, Stehouwer C, Kooy A. Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial. Diabetes Obes Metab. 2017 Jul 6. doi: 10.1111/dom.13054.